Sanofi India (500674) Q2 2025 earnings summary

Executive summary

• Board approved unaudited financial statements for the quarter and half-year ended June 30, 2025.

• Consumer Healthcare business demerged effective June 1, 2024; results now reflect continuing and discontinued operations.

• Board noted retirement of Whole-time Director and Site Director-Goa, Ms. Renee Amonkar, effective August 11, 2025.

• Appointment of Mr. Mahadev Gawade as Additional and Whole-time Director and Site Director-Goa, effective August 11, 2025.

Financial highlights

• Revenue from operations for Q2 2025: ₹4,063 million, down from ₹4,635 million in Q2 2024 and ₹5,359 million in Q1 2025.

• Net profit from continuing operations for Q2 2025: ₹695 million, up from ₹682 million in Q2 2024, but down from ₹1,195 million in Q1 2025.

• EPS from continuing operations for Q2 2025: ₹30.18, compared to ₹29.62 in Q2 2024 and ₹51.89 in Q1 2025.

• Net cash inflow from operating activities (H1 2025): ₹2,910 million, nearly flat year-over-year.

• Cash and cash equivalents as of June 30, 2025: ₹2,951 million, up from ₹2,838 million at December 31, 2024.

Outlook and guidance

• Entered a promotion and distribution agreement with Emcure Pharmaceuticals for Oral Anti-diabetic business post quarter-end.